Cantitate/Preț
Produs

Nanoparticles in Angiogenesis and Cancer: Synthesis Lectures on Biomedical Engineering

Autor Sudip Mukherjee, Vijay Sagar Madamsetty
en Limba Engleză Hardback – 18 oct 2022
This book highlights recent developments of organic and inorganic nanomedicine that play a major role in anti-angiogenic cancer therapy.  In addition, the authors present examples of nanomedicine based anti-angiogenic agents and their applications in cancer therapy.  Angiogenesis is a pathophysiological phenomenon that modulates cell proliferation and cell migration and plays important roles in cancer.  Anti-angiogenic nanotherapies have gained immense attention in recent times as alternative cost-effective therapies that opened a new dimension in cancer theranostics.  Further the challenges of the anti-angiogenic nanotherapies and possible future perspective are detailed.
Citește tot Restrânge

Din seria Synthesis Lectures on Biomedical Engineering

Preț: 62393 lei

Preț vechi: 73403 lei
-15% Nou

Puncte Express: 936

Preț estimativ în valută:
11941 12403$ 9919£

Carte disponibilă

Livrare economică 13-27 ianuarie 25

Preluare comenzi: 021 569.72.76

Specificații

ISBN-13: 9783031112836
ISBN-10: 3031112830
Pagini: 82
Ilustrații: VIII, 82 p. 27 illus., 10 illus. in color.
Dimensiuni: 168 x 240 mm
Greutate: 0.32 kg
Ediția:1st ed. 2022
Editura: Springer International Publishing
Colecția Springer
Seria Synthesis Lectures on Biomedical Engineering

Locul publicării:Cham, Switzerland

Cuprins

Chapter 1 - Introduction.- Chapter 2 - Current Anti-angiogenic Therapies and their Limitations.- Chapter 3 - Nanomedicine.- Chapter 4 - Organic Nanoparticles in Anti-angiogenic Cancer Therapy.- Chapter 5 - Inorganic Nanoparticles in Anti-angiogenic Cancer Therapy.- Chapter 6 - Potential Challenges in Anti-angiogenic Nanotherapies.- Chapter 7 - Conclusion.

Notă biografică

Sudip Mukherjee, Ph.D., is a Research Scientist at Rice University. His research interests include the development of advanced biomaterials for cell therapy, drug/gene delivery in diabetes, cancer theranostics, angiogenesis, and immunomodulatory applications. Dr. Mukherjee serves as an Associate Editor for various journals including BMC Cancer and Frontiers in Chemistry and is also a reviewer for several international journals, such as Chem Comm, Journal of Materials Chemistry A, Journal of Materials Chemistry B, ACS Nano, Biomaterials, RSC Advances, IOP Nanotechnology, and Biofabrication.
Vijay Sagar Madamsetty, Ph.D., is a senior postdoctoral fellow at the Mayo Clinic Florida in the Department of Biochemistry and Molecular Biology.  He is currently developing multiple drugs/genes encapsulating targeted nanoformulations and their preclinical evaluation in several disease animal models. Dr. Madamsetty’s research interests involve understanding key signaling pathways andhow alterations in gene expression contribute to human diseases, leading to developing effective targeted nanomedicine. He is also an active reviewer and editorial board member of several international journals. 

Textul de pe ultima copertă

This book highlights recent developments of organic and inorganic nanomedicine that play a major role in anti-angiogenic cancer therapy.  In addition, the authors present examples of nanomedicine based anti-angiogenic agents and their applications in cancer therapy.  Angiogenesis is a pathophysiological phenomenon that modulates cell proliferation and cell migration and plays important roles in cancer.  Anti-angiogenic nanotherapies have gained immense attention in recent times as alternative cost-effective therapies that opened a new dimension in cancer theranostics.  Further the challenges of the anti-angiogenic nanotherapies and possible future perspective are detailed.


Caracteristici

Provides an overview of angiogenesis and anti-angiogenesis and highlights anti-angiogenic drugs in cancer treatment Presents developments of organic and inorganic nanomedicine that play a major role in anti-angiogenic cancer therapy Includes an analysis of the limitations of nanomedicine and possible solutions that facilitate clinical translation